Novartis AG
NVS
$112.66
$0.780.70%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 10.73% | 8.96% | 9.80% | 14.82% | 7.66% |
| Total Other Revenue | 15.16% | 7.64% | 6.14% | 3.36% | -2.79% |
| Total Revenue | 10.85% | 8.92% | 9.70% | 14.48% | 7.36% |
| Cost of Revenue | 6.61% | -1.11% | -0.13% | 16.18% | 6.40% |
| Gross Profit | 12.32% | 12.56% | 13.31% | 13.92% | 7.70% |
| SG&A Expenses | 0.59% | 2.23% | 3.20% | 7.95% | 2.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -19.66% | 30.33% | 119.61% | -79.97% | 7.75% |
| Total Operating Expenses | 3.79% | -8.39% | 1.07% | 6.61% | 5.22% |
| Operating Income | 29.67% | 60.44% | 33.65% | 38.16% | 13.51% |
| Income Before Tax | 49.51% | 53.12% | 30.53% | 38.47% | 27.11% |
| Income Tax Expenses | 208.71% | -8.54% | -36.60% | -40.65% | -51.15% |
| Earnings from Continuing Operations | 39.28% | 62.19% | 42.73% | 52.34% | 41.71% |
| Earnings from Discontinued Operations | -- | 888.49% | 939.59% | 1,036.67% | 1,486.36% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 150.00% | 200.00% | 50.00% | 25.00% | -- |
| Net Income | -19.59% | 124.64% | 111.49% | 116.98% | 113.52% |
| EBIT | 29.67% | 60.44% | 33.65% | 38.16% | 13.51% |
| EBITDA | 12.94% | 38.35% | 21.15% | 25.18% | 10.23% |
| EPS Basic | -17.72% | 130.92% | 118.87% | 126.73% | 125.83% |
| Normalized Basic EPS | 33.15% | 69.45% | 41.22% | 46.65% | 22.24% |
| EPS Diluted | -17.71% | 130.18% | 118.38% | 126.83% | 125.79% |
| Normalized Diluted EPS | 33.06% | 69.56% | 41.33% | 46.87% | 22.43% |
| Average Basic Shares Outstanding | -2.76% | -3.01% | -3.62% | -4.47% | -4.97% |
| Average Diluted Shares Outstanding | -2.66% | -3.01% | -3.64% | -4.51% | -5.06% |
| Dividend Per Share | -1.44% | 13.24% | 13.24% | 13.24% | 13.24% |
| Payout Ratio | 0.31% | -0.53% | -0.50% | -0.67% | -0.55% |
